BGM Group (BGM) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed BGM Group (BGM) over the past year, gaining 4.9% versus a loss of 96.6%. Over five years, PMVP leads with a -93.8% price change compared with -98.3% for BGM. BGM Group is the larger company by market cap ($133.0 million vs $112.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | PMVP |
|---|---|---|
| Share price | $9.96 | $1.49 |
| Market cap | $133.01M | $112.51M |
| 1-day change | +6.07% | -0.67% |
| YTD return | -91.00% | +19.20% |
| 1-year return | -96.64% | +4.93% |
| 5-year return | -98.32% | -93.78% |
| EPS (TTM) | $-4.80 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $1.91 |
| 52-week low | $6.45 | $1.02 |
| Distance from 52-week high | -96.71% | -21.99% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +181.88% |
| Average volume | 6.09K | 661.39K |
| Shares outstanding | 12.69M | 75.51M |
| Employees | — | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed BGM by 101.6 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
BGM vs PMVP FAQ
Which is bigger, BGM Group or PMV Pharmaceuticals?
BGM Group (BGM) is larger, with a market capitalization of $133.01M compared with $112.51M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, BGM or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -96.64% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.